Get the Stockscreener App
4.26
13.75%
0.515
Pre-market:
4.30
0.04
+0.94%
Iovance Biotherapeutics Inc stock is traded at $4.26, with a volume of 24.50M.
It is up +13.75% in the last 24 hours and up +74.59% over the past month.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
See More
Previous Close:
$3.745
Open:
$3.8
24h Volume:
24.50M
Relative Volume:
1.90
Market Cap:
$1.75B
Revenue:
$241.53M
Net Income/Loss:
$-389.92M
P/E Ratio:
-3.4634
EPS:
-1.23
Net Cash Flow:
$-323.54M
1W Performance:
+11.23%
1M Performance:
+74.59%
6M Performance:
+93.64%
1Y Performance:
+8.67%
1-Day Range:
$3.73
$4.28
1-Week Range:
$3.50
$4.28
52-Week Range:
$1.6385
$4.35
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Name
Iovance Biotherapeutics Inc
Sector
Industry
Phone
(650) 260-7120
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
4.26 | 1.54B | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Downgrade | Goldman | Neutral → Sell |
| May-16-25 | Downgrade | UBS | Buy → Neutral |
| May-12-25 | Downgrade | Truist | Buy → Hold |
| May-09-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Jul-29-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Sep-18-23 | Reiterated | Barclays | Overweight |
| May-30-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Aug-18-22 | Resumed | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Stifel | Hold → Buy |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Jun-10-21 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| May-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-21 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| May-19-21 | Downgrade | Stifel | Buy → Hold |
| May-03-21 | Initiated | Truist | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-15-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-06-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-26-20 | Reiterated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Apr-29-19 | Initiated | Piper Jaffray | Overweight |
| Feb-28-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-07-19 | Initiated | Robert W. Baird | Outperform |
| Dec-31-18 | Resumed | B. Riley FBR | Buy |
| Jul-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Apr-10-18 | Upgrade | B. Riley FBR, Inc. | Neutral → Buy |
| Mar-13-18 | Reiterated | B. Riley FBR, Inc. | Neutral |
| Feb-23-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Jan-25-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-01-17 | Reiterated | B. Riley FBR, Inc. | Buy |
View All
Iovance Biotherapeutics Inc Stock (IOVA) Latest News
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
RSU vesting boosts Iovance (NASDAQ: IOVA) CRO share holdings - Stock Titan
Iovance Biotherapeutics (NASDAQ:IOVA) Trading 9.9% Higher After Analyst Upgrade - MarketBeat
Iovance Biotherapeutics’ TIL Therapy Showcases Promising Results - StocksToTrade
Iovance Biotherapeutics: Short-Term Pain, Long-Term GainI'm Still Bullish After All These Years - Seeking Alpha
Iovance Biotherapeutics’ Stock Rallies After Promising Trial Data - timothysykes.com
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Citizens Upgrades Iovance Biotherapeutics (IOVA) - Nasdaq
Assessing Iovance Biotherapeutics (IOVA) Valuation After Amtagvi Momentum And New Fast Track Designation - Sahm
IOVA Receives Analyst Upgrade to Market Outperform by Citizens | - GuruFocus
Citizens Jmp Upgrades Iovance Biotherapeutics (NASDAQ:IOVA) to "Market Outperform" - MarketBeat
A Glimpse Into The Expert Outlook On Iovance Biotherapeutics Through 4 Analysts - Benzinga
This Unity Software Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday - Benzinga
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Short Interest Up 24.8% in February - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Gains Visibility Across The Nasdaq Index - Kalkine Media
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
IOVA: AMTAGVI drives robust growth as pipeline advances toward major milestones in lung and sarcoma - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Why Iovance Biotherapeutics (IOVA) Is Up 34.5% After Amtagvi-Fueled Revenue Jump And Lifileucel Fast Track - simplywall.st
Iovance Lifileucel Progress Reshapes Growth Prospects Beyond Melanoma - Yahoo Finance
IOVA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Wall Street Zen Upgrades Iovance Biotherapeutics (NASDAQ:IOVA) to Hold - MarketBeat
Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Potential Upside of 132% Amid Rising Investor Interest - DirectorsTalk Interviews
Is Iovance Biotherapeutics (IOVA) Pricing Reflect Recent Cell Therapy Progress Accurately - Yahoo Finance
IOVA Should I Buy - Intellectia AI
Iovance (NASDAQ: IOVA) CCO vests 120,000 PSUs, withholds shares for tax - Stock Titan
Iovance Biotherapeutics (IOVA) Reports 61% Annual Revenue Growth Driven by Amtagvi Success - Yahoo Finance
Strategic Milestones Propel Iovance Biotherapeutics Inc. - StocksToTrade
Iovance Biotherapeutics to Present at Upcoming Conferences - ChartMill
Brokers Set Expectations for IOVA Q1 Earnings - MarketBeat
Guidance Update: Whats the beta of Iovance Biotherapeutics Inc stockQuarterly Profit Report & Smart Swing Trading Techniques - baoquankhu1.vn
1 Nearly Unknown Biotech Stock Set To Go Parabolic If Its Pipeline Hits - AOL.com
IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress - The Globe and Mail
Iovance Highlights Amtagvi Revenue Growth and Profitability Path - The Globe and Mail
Key facts: Iovance's Lifileucel gains Fast Track; Barclays raises target to $11 - TradingView
Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why - Yahoo Finance
Iovance Biotherapeutics (IOVA) Analyst Raises Price Target to $1 - GuruFocus
Iovance Biotherapeutics Surges Amid Encouraging Sarcoma Therapy Data - timothysykes.com
Barclays Boosts Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $11.00 - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Sees Strong Trading Volume Following Earnings Beat - MarketBeat
Iovance Biotherapeutics TIL Therapy Shows Promising Upside - StocksToTrade
Chardan Capital Has Lowered Expectations for Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Raised to Market Outperform at Citizens Jmp - MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2025 Earnings Call Transcript - Insider Monkey
IOVA Stock Upgraded to Market Outperform by Citizens Analyst | I - GuruFocus
Iovance Biotherapeutics stock rating upgraded on revenue growth By Investing.com - Investing.com Canada
Iovance Biotherapeutics Q4 Loss Narrows To US$0.18 EPS And Tests Bearish Narratives - simplywall.st
Iovance Biotherapeutics stock rating upgraded on revenue growth - Investing.com
Iovance Biotherapeutics Reports Record Q4 Margins and Strong Upside Potential - Intellectia AI
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits
Iovance Biotherapeutics Inc (IOVA) Q4 2025 Earnings Call Highlig - GuruFocus
Iovance Biotherapeutics Inc Stock (IOVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):